Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo

Journal of Molecular Medicine

Volumn 89, Issue 9, 2011, Pages 891-902

  Aviello, Gabriella ^a,e   Borrelli, Francesca ^a,e   Guida, Francesca ^b   Romano, Barbara ^a,e   Lewellyn, Kevin ^c   De Chiaro, Maria ^b   Luongo, Livio ^b   Zjawiony, Jordan K ^c,d   Maione, Sabatino ^b,e   Izzo, Angelo A ^a,e   Capasso, Raffaele ^a,e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF MISSISSIPPI   (United States)

^d UNIVERSITY OF MISSISSIPPI   (United States)

^e Endocannabinoid Research Group   (Italy)

Author keywords

opioid receptors (KOR); Cannabinoid receptors; Carrageenan induced; Inflammation; Lipopolysaccharide; Macrophages; Oedema; Salvinorin A

Indexed keywords

CANNABINOID 1 RECEPTOR; CARRAGEENAN; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; NALOXONE; NITRITE; NORBINALTORPHIMINE; RIMONABANT; SALVINORIN A; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CYTOTOXICITY; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PAW EDEMA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CYCLOOXYGENASE 2; DITERPENES, CLERODANE; EDEMA; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MICE; MICE, INBRED ICR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, KAPPA; SALVIA;

EID: 80052500408     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-011-0752-4     Document Type: Article

References (45)

1. LJ Valdés 3rd 1994 Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A J Psychoactive Drugs 26 277 283 7844657
2. DJ Sheffler BL Roth 2003 Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor Trends Pharmacol Sci 24 107 109 12628350 10.1016/S0165-6147(03)00027-0 1:CAS:528:DC%2BD3sXhs1Wru7k%3D (Pubitemid 36293772)
3. TA Vortherms BL Roth 2006 Salvinorin A: from natural product to human therapeutics Mol Interv 6 257 265 17035666 10.1124/mi.6.5.7 1:CAS:528: DC%2BD28Xht1ehs7vL (Pubitemid 44556046)
4. TA Munro MA Rizzacasa BL Roth BA Toth F Yan 2005 Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist J Med Chem 48 345 348 15658846 10.1021/jm049438q 1:CAS:528:DC%2BD2MXkvVOltg%3D%3D (Pubitemid 40139777)
5. EH Chartoff D Potter D Damez-Werno BM Cohen WA Carlezon Jr 2008 Exposure to the selective kappa-opioid receptor agonist salvinorin A modulates the behavioural and molecular effects of cocaine in rats Neuropsychopharmacology 33 2676 2687 18185499 10.1038/sj.npp.1301659 1:CAS:528:DC%2BD1cXhtFWhs7rM
6. CL Nemeth TA Paine JE Rittiner C Béguin FI Carroll BL Roth BM Cohen WA Carlezon Jr 2010 Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats Psychopharmacol Berl 210 263 274 10.1007/s00213-010-1834-7 1:CAS:528:DC%2BC3cXktFCnsbo%3D
7. D Braida V Capurro A Zani T Rubino D Viganò D Parolaro M Sala 2009 Potential anxiolytic- and antidepressant-like effects of salvinorin A, the main active ingredient of Salvia divinorum, in rodents Br J Pharmacol 157 844 853 19422370 10.1111/j.1476-5381.2009.00230.x 1:CAS:528:DC%2BD1MXhtVChu7jF
8. CR McCurdy KJ Sufka GH Smith JE Warnick MJ Nieto 2006 Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist Pharmacol Biochem Behav 83 109 113 16434091 10.1016/j.pbb.2005.12.011 1:CAS:528:DC%2BD28Xit1aqsbg%3D
9. R Capasso F Borrelli F Capasso DJ Siebert DJ Stewart JK Zjawiony AA Izzo 2006 The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum Neurogastroenterol Motil 18 69 75 16371085 10.1111/j.1365-2982.2005.00725.x 1:STN:280:DC%2BD2MnotlOnsw%3D%3D
10. R Capasso F Borrelli J Zjawiony L Kutrzeba G Aviello G Sarnelli F Capasso AA Izzo 2008 The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice Neurogastroenterol Motil 20 142 148 17931335 1:CAS:528:DC%2BD1cXjtFCjtLs%3D
11. R Capasso F Borrelli MG Cascio G Aviello K Huben JK Zjawiony P Marini B Romano V Di Marzo F Capasso, et al. 2008 Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors Br J Pharmacol 155 681 689 18622408 10.1038/bjp.2008.294 1:CAS:528:DC%2BD1cXht12lsrjE
12. D Braida V Limonta S Pegorini A Zani C Guerini-Rocco E Gori M Sala 2007 Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement Psychopharmacol Berl 190 441 448 10.1007/s00213-006-0639-1 1:CAS:528:DC%2BD2sXhtFygsLk%3D (Pubitemid 46204461)
13. J Fichna R Schicho CN Andrews M Bashashati M Klompus DM McKay DM McKay KA Sharkey JK Zjawiony A Janecka MA Storr 2009 Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors Neurogastroenterol Motil 21 1326 e128 19650775 10.1111/j.1365-2982.2009.01369.x 1:CAS:528:DC%2BD1MXhs1Slur3O
14. DM Walentiny RE Vann JA Warner LS King HH Seltzman HA Navarro CE Twine Jr BF Thomas AF Gilliam BP Gilmour, et al. 2010 Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents Psychopharmacol Berl 210 275 284 10.1007/s00213-010-1827-6 1:CAS:528: DC%2BC3cXktVahsr0%3D
15. RR Ji Q Zhang PY Law HH Low R Elde T Hökfelt 1995 Expression of mu-, delta-, and kappa-opioid receptor-like immunoreactivities in rat dorsal root ganglia after carrageenan-induced inflammation J Neurosci 15 8156 8166 8613750 1:CAS:528:DyaK28Xls1Ol
16. V Di Marzo 2008 Targeting the endocannabinoid system: to enhance or reduce? Nat Rev Drug Discov 7 438 455 18446159 10.1038/nrd2553 (Pubitemid 351649182)
17. RG Pertwee 2009 Emerging strategies for exploiting cannabinoid receptor agonists as medicines Br J Pharmacol 156 397 411 19226257 10.1111/j.1476-5381. 2008.00048.x 1:CAS:528:DC%2BD1MXpt1Wlsrk%3D
18. A Rossi AM Acquaviva F Iuliano R Di Paola S Cuzzocrea L Sautebin 2005 Up-regulation of prostaglandin biosynthesis by leukotriene C4 in elicited mice peritoneal macrophages activated with lipopolysaccharide/interferon-{gamma} J Leukoc Biol 78 985 991 16046553 10.1189/jlb.1004619 1:CAS:528:DC%2BD2MXhtVOrtbfF (Pubitemid 41384415)
19. F Borrelli G Aviello B Romano P Orlando R Capasso F Maiello F Guadagno S Petrosino F Capasso V Di Marzo AA Izzo 2009 Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis J Mol Med 87 1111 1121 19690824 10.1007/s00109-009-0512-x 1:CAS:528:DC%2BD1MXhtlKit73L
20. GT DeLong CE Wolf A Poklis AH Lichtman 2010 Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Π(9)- tetrahydrocannabinol Drug Alcohol Depend 112 126 133 20619971 10.1016/j.drugalcdep.2010.05.019 1:CAS:528:DC%2BC3cXhtlOhsLbO
21. FV Abbott ER Guy 1995 Effects of morphine, pentobarbital and amphetamine on formalin- induced behaviours in infant rats: sedation versus specific suppression of pain Pain 62 303 312 8657430 10.1016/0304-3959(94)00277-L 1:CAS:528:DyaK2MXptlajtLs%3D
22. J MacMicking QW Xie C Nathan 1997 Nitric oxide and macrophage function Annu Rev Immunol 15 323 350 9143691 10.1146/annurev.immunol.15.1.323 1:CAS:528:DyaK2sXisVCmsLo%3D (Pubitemid 27169284)
23. J Hawiger 2001 Innate immunity and inflammation: a transcriptional paradigm Immunol Res 23 99 109 11444396 10.1385/IR:23:2-3:099 1:CAS:528:DC%2BD3MXltFWqsLc%3D (Pubitemid 32575352)
24. CJ Morris 2003 Carrageenan-induced paw edema in the rat and mouse Meth Mol Biol 225 115 121
25. J Sawynok XJ Liu 2004 The formalin test: characteristics and usefulness of the model Rev Anal 7 145 163 10.3727/000000003783992982
26. M Grilli E Neri S Zappettini F Massa A Bisio G Romussi M Marchi A Pittaluga 2009 Salvinorin A exerts opposite presynaptic controls on neurotransmitter exocytosis from mouse brain nerve terminals Neuropharmacology 57 523 530 19628000 10.1016/j.neuropharm.2009.07.023 1:CAS:528: DC%2BD1MXhtFajsbbM
27. D Fairweather D Cihakova 2009 Alternatively activated macrophages in infection and autoimmunity J Autoimmun 33 222 230 19819674 10.1016/j.jaut.2009. 09.012 1:CAS:528:DC%2BD1MXhsVensLfF
28. P Pacher JS Beckman L Liaudet 2007 Nitric oxide and peroxynitrite in health and disease Physiol Rev 87 315 424 17237348 10.1152/physrev.00029.2006 1:CAS:528:DC%2BD2sXitVagsr8%3D (Pubitemid 46217686)
29. L Boscá M Zeini PG Través S Hortelano 2005 Nitric oxide and cell viability in inflammatory cells: a role for NO in macrophage function and fate Toxicology 208 249 258 15691589 10.1016/j.tox.2004.11.035 (Pubitemid 40187335)
30. TA Samad KA Moore A Sapirstein S Billet A Allchorne S Poole JV Bonventre CJ Woolf 2001 Interleukin-1beta-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity Nature 410 471 475 11260714 10.1038/35068566 1:CAS:528:DC%2BD3MXisFahsrs%3D (Pubitemid 32240046)
31. W Liu N Reinmuth O Stoeltzing AA Parikh C Tellez S Williams YD Jung F Fan A Takeda M Akagi, et al. 2003 Cyclooxygenase-2 is up-regulated by interleukin-1 beta in human colorectal cancer cells via multiple signaling pathways Cancer Res 63 3632 3636 12839952 1:CAS:528:DC%2BD3sXltVGrurY%3D (Pubitemid 36793046)
32. KW Moore MR de Waal RL Coffman A O'Garra 2001 Interleukin-10 and the interleukin-10 receptor Annu Rev Immunol 19 683 765 11244051 10.1146/annurev.immunol.19.1.683 1:CAS:528:DC%2BD3MXivFKgu70%3D (Pubitemid 32368050)
33. YW Liu CC Chen HP Tseng WC Chang 2006 Lipopolysaccharide-induced transcriptional activation of interleukin-10 is mediated by MAPK- and NF-kappaB-induced CCAAT/enhancer- binding protein delta in mouse macrophages Cell Signal 18 1492 1500 16413748 10.1016/j.cellsig.2005.12.001 1:CAS:528:DC%2BD28Xls1aqtLw%3D (Pubitemid 43832085)
34. D Braida V Limonta V Capurro P Fadda T Rubino P Mascia A Zani E Gori W Fratta D Parolaro, et al. 2008 Involvement of kappa-opioid and endocannabinoid system on Salvinorin A- induced reward Biol Psychiatry 63 286 292 17920565 10.1016/j.biopsych.2007.07.020 1:CAS:528:DC%2BD1cXlsVWntw%3D%3D
35. V Di Marzo T Bisogno L De Petrocellis D Melck P Orlando JA Wagner G Kunos 1999 Biosynthesis and inactivation of the endocannabinoid 2- arachidonoylglycerol in circulating and tumoral macrophages Eur J Biochem 264 258 267 10447696 10.1046/j.1432-1327.1999.00631.x (Pubitemid 29385890)
36. RB Rothman DL Murphy H Xu JA Godin CM Dersch JS Partilla K Tidgewell M Schmidt TE Prisinzano 2007 Salvinorin A: allosteric interactions at the mu-opioid receptor J Pharmacol Exp Ther 320 801 810 17060492 10.1124/jpet.106.113167 1:CAS:528:DC%2BD2sXhs1WrsrY%3D (Pubitemid 46147962)
37. P Marini AS Moriello L Cristino M Palmery L De Petrocellis V Di Marzo 2009 Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells: interactions with muscarinic and delta-opioid receptors Biochim Biophys Acta 1793 1289 1303 19445974 10.1016/j.bbamcr.2009.05. 002 1:CAS:528:DC%2BD1MXnsFyit7o%3D
38. J Guindon AG Hohmann 2008 Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain Br J Pharmacol 153 319 334 17994113 10.1038/sj.bjp.0707531 1:CAS:528:DC%2BD1cXovFCluw%3D%3D
39. T Cunha-Oliveira AC Rego CR Oliveira 2008 Cellular and molecular mechanisms involved in the neurotoxicity of opioid and psychostimulant drugs Brain Res Rev 58 192 208 18440072 10.1016/j.brainresrev.2008.03.002 1:CAS:528:DC%2BD1cXnvVOgu7Y%3D
40. RS Ames D Lee JJ Foley AJ Jurewicz MA Tornetta W Bautsch B Settmacher A Klos KF Erhard RD Cousins AC Sulpizio JP Hieble G McCafferty KW Ward JL Adams WE Bondinell DC Underwood RR Osborn AM Badger HM Sarau 2001 Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models J Immunol 166 6341 6348 11342658 1:CAS:528:DC%2BD3MXjsFCqtL8%3D (Pubitemid 32440767)
41. FM da Cunha D Duma J Assreuy FC Buzzi R Niero MM Campos JB Calixto 2004 Caffeic acid derivatives: in vitro and in vivo anti-inflammatory properties Free Radic Res 38 1241 1253 15621702 10.1080/10715760400016139 (Pubitemid 39654514)
42. R Medeiros GF Passos CE Vitor J Koepp TL Mazzuco LF Pianowski MM Campos JB Calixto 2007 Effect of two active compounds obtained from the essential oil of Cordia verbenacea on the acute inflammatory responses elicited by LPS in the rat paw Br J Pharmacol 151 618 627 17471174 10.1038/sj.bjp.0707270 1:CAS:528:DC%2BD2sXntFemtrw%3D (Pubitemid 47016295)
43. MD Schmidt MS Schmidt ER Butelman WW Harding K Tidgewell DJ Murry MJ Kreek TE Prisinzano 2005 Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates Synapse 58 208 210 16138318 10.1002/syn.20191 1:CAS:528:DC%2BD2MXhtFensrbK (Pubitemid 41443741)
44. Y Ma H Liu H Tu-Rapp HJ Thiesen SM Ibrahim SM Cole RM Pope 2004 Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation Nat Immunol 5 380 387 15004557 10.1038/ni1054 1:CAS:528:DC%2BD2cXisF2ktbs%3D (Pubitemid 38500086)
45. TJ Coderre AL Vaccarino R Melzack 1990 Central nervous system plasticity in the tonic pain response to subcutaneous formalin injection Brain Res 535 155 158 2292020 10.1016/0006-8993(90)91835-5 1:CAS:528:DyaK3MXktVemtQ%3D%3D